Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $116.2 million.

  • Pediatrix Medical's Net Cash Flow rose 2448.37% to $116.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $241.2 million, marking a year-over-year increase of 15309.75%. This contributed to the annual value of $167.4 million for FY2024, which is 13183.13% up from last year.
  • Per Pediatrix Medical's latest filing, its Net Cash Flow stood at $116.2 million for Q3 2025, which was up 2448.37% from $128.1 million recorded in Q2 2025.
  • In the past 5 years, Pediatrix Medical's Net Cash Flow registered a high of $128.1 million during Q2 2025, and its lowest value of -$873.3 million during Q1 2021.
  • Over the past 5 years, Pediatrix Medical's median Net Cash Flow value was $11.4 million (recorded in 2024), while the average stood at -$37.4 million.
  • Examining YoY changes over the last 5 years, Pediatrix Medical's Net Cash Flow showed a top increase of 424690.91% in 2024 and a maximum decrease of 166378.38% in 2024.
  • Pediatrix Medical's Net Cash Flow (Quarter) stood at $60.3 million in 2021, then tumbled by 92.1% to $4.8 million in 2022, then soared by 1072.2% to $55.8 million in 2023, then soared by 129.09% to $127.9 million in 2024, then fell by 9.18% to $116.2 million in 2025.
  • Its Net Cash Flow stands at $116.2 million for Q3 2025, versus $128.1 million for Q2 2025 and -$131.0 million for Q1 2025.